한글목차

VXA-A1.1 신약의 주요 7 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동 인사이트, 시장 예측 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 계절성 인플루엔자에서 VXA-A1.1의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시된 치료법)

제4장 경쟁 구도(후기 신규 치료법)

제5장 VXA-A1.1 시장 평가

• 계절성 인플루엔자에서 VXA-A1.1 시장 전망
• 주요 7시장 분석
  • 주요 7 시장 계절성 인플루엔자용 VXA-A1.1의 시장 규모
• 시장 분석 : 국가별
  • 미국의 계절성 인플루엔자용 VXA-A1.1의 시장 규모
  • 독일의 계절성 인플루엔자용 VXA-A1.1의 시장 규모
  • 영국의 계절성 인플루엔자용 VXA-A1.1의 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"VXA-A1.1 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about VXA-A1.1 for seasonal influenza in the seven major markets. A detailed picture of the VXA-A1.1 for seasonal influenza in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the VXA-A1.1 for seasonal influenza. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VXA-A1.1 market forecast analysis for seasonal influenza in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in seasonal influenza.

Drug Summary:

VXA-A1.1, an investigational oral tablet flu vaccine under development by Vaxart, had cellular correlates of protection against influenza infection. VXA-A1.1 utilizes TLR adjuvant by encoding dsRNA and an H1N1 HA transgene in a recombinant adenovirus type 5 (Ad5) vector. TLR adjuvant is double-stranded RNA (dsRNA), which binds TLR3 and activates inflammatory pathways. This oral vaccine has been studied in four clinical trials with 285 participants between 18 years and 49 years. One trial reported increased antibody responses to matched H1N1 strains with an average of 7.7-fold increases in HAI titers and 29-fold increases in microneutralization titers after vaccination.

It is a prophylactic vaccine candidate that targets a range of infectious diseases, including SARS-CoV-2 (the virus that causes coronavirus disease 2019 ("COVID-19")), norovirus (a widespread cause of acute gastro-intestinal enteritis), seasonal influenza and respiratory syncytial virus ("RSV").

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the VXA-A1.1 description, mechanism of action, dosage and administration, research and development activities in seasonal influenza.
• Elaborated details on VXA-A1.1 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VXA-A1.1 research and development activities in seasonal influenza across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VXA-A1.1.
• The report contains forecasted sales of VXA-A1.1 for seasonal influenza till 2032.
• Comprehensive coverage of the late-stage emerging therapies for seasonal influenza.
• The report also features the SWOT analysis with analyst views for VXA-A1.1 in seasonal influenza.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VXA-A1.1 Analytical Perspective by DelveInsight

• In-depth VXA-A1.1 Market Assessment

This report provides a detailed market assessment of VXA-A1.1 for seasonal influenza in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• VXA-A1.1 Clinical Assessment

The report provides the clinical trials information of VXA-A1.1 for seasonal influenza covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for seasonal influenza is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VXA-A1.1 dominance.
• Other emerging products for seasonal influenza are expected to give tough market competition to VXA-A1.1 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VXA-A1.1 in seasonal influenza.
• Our in-depth analysis of the forecasted sales data of VXA-A1.1 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VXA-A1.1 in seasonal influenza.

Key Questions

• What is the product type, route of administration and mechanism of action of VXA-A1.1?
• What is the clinical trial status of the study related to VXA-A1.1 in seasonal influenza and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VXA-A1.1 development?
• What are the key designations that have been granted to VXA-A1.1 for seasonal influenza?
• What is the forecasted market scenario of VXA-A1.1 for seasonal influenza?
• What are the forecasted sales of VXA-A1.1 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to VXA-A1.1 for seasonal influenza?
• Which are the late-stage emerging therapies under development for the treatment of seasonal influenza?

Table of Contents

1. Report Introduction

2. VXA-A1.1 Overview in seasonal influenza

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. VXA-A1.1 Market Assessment

• 5.1. Market Outlook of VXA-A1.1 in seasonal influenza
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of VXA-A1.1 in the 7MM for seasonal influenza
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of VXA-A1.1 in the United States for seasonal influenza
  • 5.3.2. Market Size of VXA-A1.1 in Germany for seasonal influenza
  • 5.3.3. Market Size of VXA-A1.1 in France for seasonal influenza
  • 5.3.4. Market Size of VXA-A1.1 in Italy for seasonal influenza
  • 5.3.5. Market Size of VXA-A1.1 in Spain for seasonal influenza
  • 5.3.6. Market Size of VXA-A1.1 in the United Kingdom for seasonal influenza
  • 5.3.7. Market Size of VXA-A1.1 in Japan for seasonal influenza

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options